ABSTRACT: Advanced pancreatic ductal adenocarcinoma remains a clinical challenge. Only a third of patients receiving FOLFIRINOX combination chemotherapy displays tumour downstaging. Because of their high stability in plasma, especially in extracellular vesicles, microRNAs (miRNAs) hold great promise as a new class of minimally invasive biomarkers. Our aim was to identify differently expressed, blood-based miRNAs to select and monitor patients with advanced pancreatic ductal adenocarcinoma who would benefit from FOLFIRINOX.
Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma / Meijer, LL; Frampton, AE; Garajova, I; Caparello, C; Le Large, TYS; Funel, N; Vasile, E; Stebbing, J; Krell, J; Kazemier, G; Giovannetti, E. - In: THE LANCET. - ISSN 0140-6736. - ELETTRONICO. - 389:Supplement 1(2017), pp. 43.68-43.68. (Intervento presentato al convegno Spring Meeting on Clinician Scientists in Training tenutosi a London, ENGLAND nel FEB 23, 2017).
Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma
Garajova, I;Giovannetti, E
2017
Abstract
ABSTRACT: Advanced pancreatic ductal adenocarcinoma remains a clinical challenge. Only a third of patients receiving FOLFIRINOX combination chemotherapy displays tumour downstaging. Because of their high stability in plasma, especially in extracellular vesicles, microRNAs (miRNAs) hold great promise as a new class of minimally invasive biomarkers. Our aim was to identify differently expressed, blood-based miRNAs to select and monitor patients with advanced pancreatic ductal adenocarcinoma who would benefit from FOLFIRINOX.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
